



Cite this: *RSC Adv.*, 2020, **10**, 15579

## Reasons for enhanced activity of doxorubicin on co-delivery with octa(3-aminopropyl)silsesquioxane†

Kinga Piorecka, \* Jan Kurjata, Irena Bak-Sypien, Marek Cypryk, Urszula Steinke and Włodzimierz A. Stanczyk

This paper presents results of spectroscopic (NMR, FTIR, fluorescence), Q-TOF mass spectrometry and Z-potential analyses of interactions between octa(3-aminopropyl)silsesquioxane hydrochloride (POSS-NH<sub>2</sub>·HCl) and anticancer drug – doxorubicin hydrochloride. These studies aimed at explanation of the enhanced activity of doxorubicin on co-delivery with POSS-NH<sub>2</sub>. The results point to the formation of active complexes *via* ionic interactions between the ammonium chloride groups of silsesquioxane and the drug, and not, as suggested earlier, *via* NH···N hydrogen bonding. It has also been shown that the main driving force for the formation of the complexes can be strengthened by  $\pi$ – $\pi$  stacking and hydrogen bonds. The experimental results are supported by quantum mechanical calculations. This work has proven that co-delivery with POSS offers a potentially advantageous and simple approach for improved efficacy in chemotherapy, avoiding often complicated synthesis of conjugates, involving covalent bonding between drug, nanocarrier and targeting agents.

Received 11th February 2020  
 Accepted 13th April 2020

DOI: 10.1039/d0ra01319f  
[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

### Introduction

The anthracycline antibiotic doxorubicin (DOX) is an anti-cancer drug that is highly effective in the clinical treatment of a wide variety of tumours. Currently proposed mechanisms of its action include intercalation with the DNA helix, disrupting gene expression and leading to cancer cell death.<sup>1–3</sup> However, administration of doxorubicin can be limited by the occurrence of undesirable side effects such as cardiotoxicity and inherent drug resistance. Drug delivery nano-systems offer important approach that can improve antitumour activity, decreasing at the same time toxicity of doxorubicin. Prodrugs, conjugated or complexed with nanocarriers (1–100 nm) can easily overcome the barriers constituted by biological membranes. Such the systems improve selective distribution of the active drug, increase time of its activity and thus, can lead to dose reduction.<sup>4</sup> It is worth to underline that during the last 5–7 years almost 200 research papers have been published, devoted to studies of novel anthracycline (mainly doxorubicin) nano-conjugates<sup>5</sup> and nanocomplexes.<sup>6</sup> Many anthracycline nanocarriers such as graphene oxide, poly(lactide-*co*-glycolide), polyamidoamine dendrimers (PAMAM) and fatty acids have been described so far.<sup>7,8</sup> For some time now we have been

studying polyhedral oligomeric silsesquioxanes (POSS)<sup>9</sup> as anthracycline nanocarriers that are often referred to as the next generation of materials for biomedical applications.<sup>10</sup> Important features of POSS derivatives are their biocompatibility, biodegradability, nanometer size and lack of toxicity (the product of their metabolism is orthosilicic acid).<sup>11–15</sup> In the course of our studies on synthesis of novel POSS-DOX covalent conjugates,<sup>16</sup> we turned our attention to the observation that simple co-delivery of POSS and DOX led to unexpected increased efficacy of the drug towards HeLa and MCF-7 cell lines. The results pointed out that IC<sub>50</sub> values for POSS:DOX complex towards MCF-7 and HeLa cell lines were respectively 2.69 ± 0.15, and 0.92 ± 0.09  $\mu\text{M L}^{-1}$ , compared to 17.44 ± 5.23 and 1.45 ± 0.15  $\mu\text{M L}^{-1}$  for free doxorubicin. It clearly suggested highly increased transport effectiveness of DOX to the cells due to the use of octa(3-aminopropyl)silsesquioxane as the complexing nanocarrier.<sup>17</sup> Similar phenomenon was also reported earlier by Ohta *et al.*, for interaction of amino-modified silicon quantum dots and doxorubicin. They demonstrated that such species that were named as Si-QD aggregates, were internalized by HepG2 cells and could function as anticancer agents.<sup>18</sup> In both these reports the authors proposed NH···N hydrogen bonding as a driving force for complex (aggregates) formation, but it was only an experimentally unsupported suggestion. Thus, the current paper focuses on analysing the mechanism of interaction between POSS and doxorubicin, and potential formation of active complexes involving POSS functional aminopropyl groups and the anthracycline functional groups. It appears generally important also for other anticancer drug complexing

Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Łódź, Poland. E-mail: [kgradzin@cbmm.lodz.pl](mailto:kgradzin@cbmm.lodz.pl); Tel: +48-42-6803-203

† Electronic supplementary information (ESI) available: Computer simulation and analytical data. See DOI: [10.1039/d0ra01319f](https://doi.org/10.1039/d0ra01319f)






Fig. 1 Scheme of co-delivery of POSS-NH<sub>2</sub> and DOX into the cells.

systems, once the presence of required functional groups for such the interactions with POSS are identified. We applied spectroscopic methods – NMR, FTIR, fluorescence, mass spectrometry, FTIR, Z-potential measurements and computational simulations. The 8 : 1 molar complexes of DOX:POSS were analysed as it was found that they exhibited the highest cytotoxic activity when compared to co-delivery of 1 : 1, 2 : 1 and 4 : 1 systems (Fig. 1).<sup>17</sup>

## Materials and methods

Octa(3-aminopropyl)silsesquioxane (POSS-NH<sub>2</sub>) (**1**) was synthesized as described in the literature.<sup>19</sup> Doxorubicin hydrochloride was obtained from Sigma Aldrich. Dimethyl-d6-sulfoxide (99.8 atom %D, ARMAR) and phosphate buffer saline PBS pH 7.4 were used as supplied by Merck. The parameters used to determine interaction between doxorubicin and POSS are shown in Table 1. Doxorubicin was dissolved in PBS (pH 7.4)/DMSO-d6 or H<sub>2</sub>O, then filtered and added to the POSS solution in the same solvent. The experiments were carried out in oven-dried, foil-wrapped glassware, under Ar, protected from the light. NMR spectra were recorded on 500 MHz Bruker AVANCE instrument at 300 K. Chemical shifts are reported in ppm downfield from TMS, using DMSO-d6 as a solvent. The FTIR spectra were obtained from 64 scans at a 2 cm<sup>-1</sup> resolution with a Nicolet 6700 spectrometer equipped with a deuterated triglycine sulfate detector. Attenuated total reflectance (ATR) system was used in this method.

The fluorescence spectra were measured in quartz cuvettes using a HORIBA, Jobin Yvon spectrofluorometer at 37 °C. The widths of the excitation and emission slits were set to 3 nm. Zeta potential was determined using a Zetasizer-Nano-Z (Malvern

Instrument, UK) equipped with a He-Ne laser ( $\lambda = 633$  nm). Measurements for DOX-POSS system were performed at 10<sup>-3</sup> M of phosphate buffer saline solution at 37 °C. The results are given as the average of 10 measurements from the intensity distribution curves. All MS analyses were carried out using a hybrid Q-TOF-MS instrument (SYNAPT G2-Si HDMS Waters, Beverly, MA) equipped with an ESI interface. The instrument was operated in positive mode, using the following settings: capillary voltage 3.0 kV, sampling cone voltage and source offset established at 150 V for both, source temperature 100 °C, and desolvation gas temperature 250 °C. Nitrogen was used as both cone and de-solvation gas at flow rates of 20 and 450 L h<sup>-1</sup>, respectively. Nebulizer pressure was fixed at 6.5 bar. MS data were acquired in the range *m/z* 500–5000. The TOF analyser was operated in resolution mode. Sample solutions were introduced by direct infusion at a flow rate 15  $\mu$ L min<sup>-1</sup> via the electrospray interface of the mass spectrometer. To ensure accurate mass data the measurements were corrected during acquisition using sodium iodide solution as a calibrant and leucine enkephalin solution ([M + H]<sup>+</sup> 556.2771 Da) as look mass. The results of the measurements were processed using the MassLynx 4.2 software (Waters). ESI mass spectra were deconvoluted using Waters MassLynx MaxEnt 3 software. Quantum mechanical calculations were performed using the Gaussian 09 suite of programs.<sup>20</sup> Geometries of the bases and base pair model systems were optimized using the hybrid B3LYP density functional<sup>21</sup> corrected for dispersion interactions using Grimme GD3 empirical term<sup>22</sup> and the 6-31+G(d) basis set in the gas phase. This level of theory was denoted as B3LYP-GD3/6-31+G(d). All stationary points were identified as stable minima by frequency calculations. The vibrational analysis provided thermal enthalpy and entropy corrections at 298 K within the rigid rotor/harmonic oscillator/ideal gas approximation.<sup>20</sup> Thermochemical corrections were scaled by a factor of 0.98. Calculations in solution were performed within a continuum model using CPCM method.<sup>23</sup> Larger species such as doxorubicin dimers and conjugates with POSS were modelled using the PM3 and PM7 semi-empirical methods using Mopac 2016 program<sup>24</sup> since implementation of these methods in Gaussian 16 leads to numerical instabilities.

## Results and discussion

### NMR and FTIR studies

NOESY NMR measurements allow to determine, basing on cross peaks, which protons of DOX interact with aminopropyl

Table 1 Description of the reaction parameters

Technique	Concentration of DOX	Solvent	Reaction temperature	DOX : POSS
NOESY NMR	8.621 × 10 <sup>3</sup> $\mu$ M	DMSO-d6	25 °C	8 : 1
Mass spectroscopy	50 $\mu$ M	H <sub>2</sub> O	37 °C	
Z-potential		PBS pH 7.4		
Fluorescence spectroscopy				
FTIR	4.44 × 10 <sup>-3</sup> g mL <sup>-1</sup>			






Fig. 2 2D NOESY spectrum of DOX with POSS-NH<sub>2</sub> at the molar ratio 8 : 1 in DMSO-d<sub>6</sub> (300 K, 500 MHz).

groups of POSS, being spatially close. In order to see OH protons the measurements were performed in aprotic solvent – DMSO. NOESY spectrum of the DMSO-d<sub>6</sub> solution of doxorubicin-POSS mixture at 8 : 1 molar ratio, in DMSO, is shown in Fig. 2. Cross-correlation peaks for amine hydrochloride and hydroxy groups of doxorubicin (marked in red) and amine groups of POSS (marked in blue) were identified.

Protons of the POSS propylamino groups (~8 ppm) correlate with such DOX groups as: NH<sub>2</sub>-HCl (~8 ppm); OH<sub>9</sub>, OH<sub>4'</sub> (~5.5 ppm); H<sub>1'</sub> (~5.3 ppm); OH<sub>14</sub>, H<sub>7</sub> (~5 ppm); H<sub>14</sub> (~4.5 ppm); OMe (~4 ppm); H<sub>3'</sub> (~3.4 ppm); H<sub>6'</sub> (~1 ppm) OH<sub>Ar</sub> (~13–14 ppm). The strongest interaction can be attributed to 3' and NH<sub>2</sub>-HCl protons. The correlations between amine groups of POSS with the 1', 3', 6', 7 and 14 protons can be explained by the close proximity of the electronegative ether moieties (1', 6', 7), amino group (3') and carbonyl group (14). Additionally, NOESY spectrum shows the intermolecular interactions of doxorubicin OH<sub>Ar</sub> groups originating from the  $\pi$ - $\pi$  stacking of anthracycline rings. As discussed in our earlier report,<sup>17</sup> the effect of hydrodynamic diameter increase on mixing both components can be explained by network-forming interactions involving doxorubicin aggregates<sup>25</sup> as well as doxorubicin-POSS complexes. With an increase in the concentration of doxorubicin in the sample,

the size of complexes decreased, thus confirming the results obtained by the MTT assay, wherein the cytotoxicity effect of the POSS:DOX complex at a molar ratio of 1 : 8 was the highest.<sup>17</sup> Intermolecular interactions can be also observed from cross peaks for OH<sub>Ar</sub> and doxorubicin OH<sub>14</sub> as well as NH<sub>2</sub>-HCl protons. In order to further characterize the DOX-POSS complex, FTIR spectroscopy was used for the solution of DOX with POSS in PBS (pH 7.3) after 24 h at 37 °C (Fig. 3). The doxorubicin to POSS molar ratio was 8 : 1 at concentration DOX in PBS of  $4.44 \times 10^{-3}$  g mL<sup>-1</sup>. Independently, at the same parameters a spectrum of doxorubicin in PBS was recorded to exclude its possible interactions with PBS. After incubation at relevant temperatures both samples were dried on a vacuum line and analyzed. The FTIR spectra of DOX and DOX-POSS complex are presented in Fig. 1, ESI.† The FTIR spectrum of DOX indicated characteristic maxima at 3368 cm<sup>-1</sup> ( $\nu_{\text{O-H}}$ ,  $\nu_{\text{N-H}}$ ); 2940 cm<sup>-1</sup> ( $\nu_{\text{C-H}}$ ); 1723 cm<sup>-1</sup> ( $\nu_{\text{C=O}}$  ketone); 1615 cm<sup>-1</sup> ( $\nu_{\text{C=O}}$  aromatic); 1577 cm<sup>-1</sup> ( $\nu_{\text{C=C}}$  aromatic). In contrast, the spectrum of complex DOX-POSS indicated that the absorbance intensity for ketone group ( $\nu_{\text{C=O}}$  ketone, 1723 cm<sup>-1</sup>) was reduced.<sup>25</sup> It points to the interaction of propylamine hydrochloride group of POSS with the ketone group (C=O in position 13) by






Fig. 3 Deconvoluted electrospray ionization mass spectrometry spectrum of DOX-POSS complex after 24 h incubation (37 °C) in H<sub>2</sub>O.

reducing electron density on the oxygen atom. These results complement and confirm the above NOESY NMR studies.

### Mass spectrometric studies

The interactions between DOX and POSS were also studied by mass spectrometry. Under ESI conditions, octakis (3-ammonium propyl)-octasilsesquioxane hydrochloride generates a protonated molecule with eight propylamine substituents,  $[(\text{POSS}-\text{(nPrNH}_2)_8) + \text{H}]^+$ , exactly mass measured at  $m/z$  881.2848 ( $\text{C}_{24}\text{H}_{65}\text{N}_8\text{O}_{12}\text{Si}_8$ ). Additional signals with  $m/z$  863.3, 845.3, 827.3 correspond to three subsequent stages of dehydration resulting from energy transferred to the precursor  $m/z$  881 (Fig. 2, ESI†). The concentration of DOX in deionized water was 50  $\mu\text{M}$ . Fig. 3, ESI† presents the ESI MS spectrum of doxorubicin incubated in water for 24 h (37 °C). Two peaks were observed which correspond to the dimeric (1087.28  $m/z$ ) and trimeric (1630.34  $m/z$ ) form of doxorubicin molecules. It is known that doxorubicin itself can form intermolecular hydrogen-bonded complexes.<sup>25</sup> Another possibility of intermolecular agglomeration is the  $\pi$ - $\pi$  stacking of anthracene rings.<sup>26–28</sup> ESI mass spectrum of the complex DOX:[POSS-(nPrNH<sub>2</sub>)<sub>8</sub>] shows a series of protonated multi-charged ions with states of charge distribution. ESI MS experimental spectrum of complex 6DOX:(POSS-(nPrNH<sub>2</sub>)<sub>8</sub>) and simulated isotopic patterns were presented on Fig. 4 (see ESI†).

Products of dehydration of the POSS is observed but with no decomposition of the complex. Fig. 3 show deconvoluted spectra of DOX:(POSS-(nPrNH<sub>2</sub>)<sub>8</sub>) complex, in which the interaction of several (6–11) DOX molecules on one POSS-(nPrNH<sub>2</sub>)<sub>8</sub> was identified (see ESI† Table 1).

### Structural features of doxorubicin

We have identified four conformers differing in the intramolecular hydrogen bond pattern. The intramolecular hydrogen bonds between OH groups in 6 and 11 positions of anthracene fragment with oxygen atoms in 5 and 12 positions




Fig. 4 The most stable conformer of doxorubicin in the gas phase (by ca 1.5 kcal mol<sup>-1</sup> more stable than the next stable one) optimized with B3LYP-GD3/6-31+G(d). The intramolecular hydrogen bonds are marked with dashed lines.

occur in all conformers.<sup>29</sup> The most stable conformer shown in Fig. 4, reveals also hydrogen bonds between OH(14) and O(13), OH(9) and O(7), OH(4') and NH<sub>2</sub> (structure 1, see ESI†).

### Model studies of intermolecular interactions involving

To study the intermolecular hydrogen bonding, in order to save computational time we constructed the simpler model which contained key functional groups of doxorubicin, namely,  $\alpha$ -hydroxy ketone group  $\alpha$ -hydroxy amine group, which are capable of strong hydrogen bond formation (Fig. 5).

It can easily be noticed that in DFT optimized structure of hydrochloride **1-HCl** the proton from HCl is transferred to the amino group and the vicinal hydroxyl group is engaged in stabilization of the chloride anion. Free energy of complex formation,  $\Delta G$ , is  $-2.8$  kcal mol<sup>-1</sup> in the gas phase, and  $-17.2$  kcal mol<sup>-1</sup> in water solution ( $\Delta H = -11.9$  and  $-26.4$  kcal mol<sup>-1</sup>, respectively). The higher energy in water results from the fact that two neutral, less solvated molecules form an ionic pair solvated much more strongly, therefore an additional energy effect of about 15 kcal mol<sup>-1</sup> results from the difference in solvation energy between the substrates and the ionic product.

There are three possibilities for binding two substrate molecules (Fig. 5, see ESI†) – the one involving both amine hydrochloride ion pairs (structure a); the one where amine





Fig. 5 Structures of 1-((1S,3R,4S)-4-amino-3-hydroxycyclohexyl)-2-hydroxyethan-1-one (1) and 1-((1S,3R,4S)-4-amino-3-hydroxycyclohexyl)-2-hydroxyethan-1-one hydrochloride (1-HCl).



Table 2 Free energies of dimerization in the gas phase and in water (kcal mol<sup>-1</sup>) at 25 °C (B3LYP-GD3/6-31+G(d))

	$\Delta H_{\text{gas}}$	$\Delta G_{\text{gas}}$	$\Delta H_{\text{water}}$	$\Delta G_{\text{water}}$	$K_{\text{eq}} (\text{H}_2\text{O})$
(a) Dimer $\sim \text{NH}_3^+\text{Cl}^- \cdots \text{ClNH}_3^- \sim$	-34.0	-21.9	-13.7	-2.1	36.5
(b) Dimer $\sim \text{NH}_3^+\text{Cl}^- \cdots \text{HOCOC}^- \sim$	-24.9	-10.0	-12.1	-0.3	1.5
(c) Dimer $\sim \text{COCOH}^- \cdots \text{HOCOC}^- \sim$	-16.5	-2.3	-11.3	-0.03	1.1

Fig. 6 Example of conformation of the doxorubicin hydrochloride dimer linked through an  $\text{NH}_3^+\text{Cl}^-$  bridge optimized with HF/3-21G\* method.

hydrochloride group from one molecule is binding the hydroxy ketone group from the other (structure b); and that involving both hydroxyl ketone groups (structure c). Thus, the complex a is additionally stabilized by the hydrogen bonds from the vicinal OH groups. The enthalpies and free energies of dimerization are collected in Table 2. As one can see, the strongest interaction in this system is the interaction of  $\text{NH}_3^+\text{Cl}^-$  ion pairs with each other (structure a). An equilibrium constant  $K \approx 36$  indicates that such dimers dominate in solution over the monomeric systems. Other types of complexes are more weakly bound and are present in much smaller concentration.

Larger aggregates of *via* amine hydrochloride moieties, even tetramers are possible provided that steric congestion is not prohibitive. Below the structures of cage and ladder-like structures of simple hydroxy amine hydrochloride tetramers are presented (Fig. 6, see ESI†). Doxorubicin hydrochloride can also form ladder tetramer, according to semi-empirical PM3 calculations (Fig. 7, see ESI†).

The other possibility of intermolecular interaction is the  $\pi$ -stacking of anthracene rings. The stacking energy in neutral doxorubicin was calculated with DFT method with correction for dispersion forces (at the B3LYP-GD3/6-31+G(d) level). The geometries of the two dimeric forms in the gas phase were calculated to compare their relative stability. A parallel form (A) is more stable by  $\Delta E = 7.6$  kcal mol<sup>-1</sup>. The antiparallel structure (B) seems to be less stable since the formation of intermolecular hydrogen bonds in this complex is very limited. In both dimers the dispersion forces are essential (Fig. 8, see ESI†).


Doxorubicin easily gets protonated by HCl forming the ion pair. The most stable conformer found by means of conformational analysis in the gas phase is shown in Fig. 9 (see ESI†). The complex formation enthalpy and free energy are  $\Delta H = -10.9$  kcal mol<sup>-1</sup>,  $\Delta G = -1.3$  kcal mol<sup>-1</sup>.

Further calculations were performed using the semi-empirical PM3 and PM7 methods to study dimers and higher assembled structures. The PM7 method apart from hydrogen bonding can reproduce also  $\pi$ - $\pi$  stacking. We tested this method together with B3LYP/6-31+G(d) for doxorubicin and doxorubicin hydrochloride dimers. For example, the PM7 geometry of parallel doxorubicin hydrochloride dimer shown in Fig. 6 is very close to that optimized at the DFT level. The PM7 dimerization enthalpy of -44.9 kcal mol<sup>-1</sup> is in excellent agreement with the B3LYP electronic energy of dimerization of -43.7 kcal mol<sup>-1</sup>. Thus we believe that using PM7 modelling method we can obtain a reliable picture of bonding in the higher associates of doxorubicin with POSS. A number of conformations of the dimer linked through the  $\text{NH}_3^+\text{Cl}^-$  bridge were found.

The example of an 'open' conformation is illustrated in Fig. 6. Conformation of the doxorubicin hydrochloride dimer linked through an  $\text{NH}_3^+\text{Cl}^-$  bridge and additionally bound by intramolecular parallel  $\pi$ - $\pi$  stacking illustrated in Fig. 10 (see ESI†). The alternative conformation involving only  $\pi$ - $\pi$  stacking (antiparallel) is also possible (Fig. 11, see ESI†). The DFT electronic energy of bonding (dimerization) in these structures are 23.7, 43.7 and 8.8 kcal mol<sup>-1</sup> respectively. Thus, the antiparallel dimer linked by  $\pi$  stacking forces only is the most weakly bound while the parallel one, where both ionic hydrogen bonding and  $\pi$  stacking operate, is the most strongly bound. It is very likely that doxorubicin hydrochloride exists in solution in larger associates in which the molecules are bound by hydrogen bonds and stacking forces, as for example in Fig. 12 (see ESI†).

### Model studies of intermolecular interactions between doxorubicin hydrochloride and POSS

Analogous interactions can occur when octa-(3)-aminopropylsilsesquioxane ( $T_8$ ) hydrochloride (Fig. 7) is present in

Fig. 7 Octa-(3)-aminopropylsilsesquioxane ( $T_8$ ) hydrochloride optimized by PM7 method. Note that  $\text{NH}_3^+\text{Cl}^-$  groups interact with each other forming intramolecular network of hydrogen bonds.




Fig. 8 Example conformation of  $T_8$  cage linked with eight doxorubicin hydrochloride molecules optimized by PM7 method.

solution. Interaction of the  $T_8$  cage and excess of doxorubicin hydrochloride leads to the complex linked by the  $\text{NH}_3^+\text{Cl}^-$  bridges. There is a large number of conformations possible, one of which is presented in Fig. 7. Due to a large number of conformations of this aggregate, the precise calculation of energetics of the complex formation is very tedious and was not performed in detail. It can be seen in Fig. 8 that the doxorubicin arms are flexible enough to interact with each other *via* the  $\pi$ -stacking or by hydrogen bonds. It is also possible to form higher aggregates *via* intermolecular interactions, however such interactions are probably less probable than intramolecular ones due to steric and entropic reasons.

### Z potential and fluorescence analysis

The measurements of the Z-potential in PBS solution can provide information about POSS and complex POSS:DOX surface charges. Z-potential was measured for a DOX : POSS system in ratio 8 : 1 and for POSS itself to compare the results. The analysis was performed for 50  $\mu\text{M}$  DOX concentration in PBS at 37 °C. The concentration of POSS was the same in two samples. The measurement was made 15 minutes and 24 h after mixing the substance (Fig. 13, ESI†). The tested silsequioxane POSS were negatively charged ( $-25 \text{ mV}$  [0 h]  $\rightarrow$   $-27 \text{ mV}$  [24 h]), but DOX : POSS (8 : 1) complex was positive ( $9 \text{ mV}$  [0 h]  $\rightarrow$   $6 \text{ mV}$  [24 h]). The interaction between POSS and DOX caused a significant change in Z-potential. After POSS was mixed with the DOX at 1 : 8 molar ratio, Z-potential turned to positive value and the mean hydrodynamic diameter increased up to  $\sim 100 \text{ nm}$ .<sup>17</sup> The positive charge of DOX:POSS complex can increase interaction with negatively charged biological membranes and make drug delivery more efficient.<sup>27</sup> Fluorescence spectrophotometry was performed to check the stability of the DOX : POSS complex (8 : 1). This complex was prepared by incubation DOX with POSS at 37 °C as a final concentration DOX in PBS to 50  $\mu\text{M}$ . The fluorescence intensity of DOX:POSS remained constant during 48 h (Fig. 14, ESI†). This result

indicates the stability of POSS:DOX complex and hindered aggregation of drug. Higher stability allows the DOX:POSS complex to circulate in the blood for longer time and increase its accumulation at the target site. The effects of the amount of drug (DOX : POSS 8 : 1), hydrodynamic diameter ( $\sim 100 \text{ nm}$ ), positive charge ( $\sim 27 \text{ mV}$ ) and stability at physiological conditions (PBS buffer) explains profound increase of cytotoxicity of the DOX:POSS complex compared to DOX.<sup>17</sup>

## Conclusions

In this study, we have shown that octa(3-aminopropyl) silsesquioxane hydrochloride (POSS-NH<sub>2</sub>·HCl) can interact non-covalently with doxorubicin hydrochloride (DOX·HCl). The complexes were characterized by NMR, FTIR, fluorescence spectroscopy, mass spectrometry and Z-potential. Experimental results were supported by quantum mechanical calculations. The latter ones have led to the conclusion that the strongest interactions occur between amine hydrochloride groups of POSS and analogous moieties of doxorubicin, and not NH···N hydrogen bonding as suggested previously.<sup>17,18</sup> They are additionally strengthened by intermolecular interactions of doxorubicin moieties themselves in 8 (DOX) to 1 (POSS) molar complex ( $\pi$ - $\pi$  stacking and hydrogen bonds). There appear thus two reasons why co-delivery of POSS with DOX led to higher anticancer activity than for DOX itself.<sup>17</sup> As discussed in the literature<sup>23–25</sup> and shown in this research doxorubicin easily forms oligomeric complexes itself in solution. On co-delivery with POSS, individual doxorubicin molecules form complexes with the POSS carrier. The other factor is the well-known high ability of POSS to penetrate cell membranes.<sup>30</sup> Both these properties of POSS-NH<sub>2</sub>·HCl-DOX system appear to interplay and lead to improved activity on co-delivery of POSS and DOX. These results can point to a useful and simple way of improving efficacy of chemotherapy also for other drug-POSS systems, provided they contain functional groups assuring such weak but efficient interactions.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The financial support for this study was provided by the Centre of Molecular and Macromolecular Studies. K. Piorecka wishes to acknowledge the Preludium Grant UMO-2016/21/N/ST5/03360. DFT calculations were supported by the PL-Grid infrastructure.

## Notes and references

- 1 N. Zhao, M. C. Woodle and A. J. Mixson, *J. Nanomed. Nanotechnol.*, 2018, **9**(5), 1000519.
- 2 D. Agudelo, P. Bourassa, G. Bérubé and H.-A. Tajmir-Riahi, *Int. J. Biol. Macromol.*, 2014, **66**, 144–150.



3 S. Malla, N. P. Niraula, K. Liou and J. K. Sohng, *Res. Microbiol.*, 2010, **161**, 109–117.

4 A. Aluigia, M. Ballestria, A. Guerrinia, G. Sotgiua, C. Ferronia, F. Corticellib, M. B. Gariboldic, E. Montic and G. Varchia, *Mater. Sci. Eng., C*, 2018, **90**, 476–484.

5 K. Piorecka, D. Smith, J. Kurjata, M. Stanczyk and W. A. Stanczyk, *Bioorg. Chem.*, 2020, **96**, 103617.

6 K. Piorecka, J. Kurjata, M. Stanczyk and W. A. Stanczyk, *Biomater. Sci.*, 2018, **6**, 2552–2565.

7 M. Marcinkowska, E. Sobierajska, M. Stanczyk, A. Janaszewska, A. Chworoś and B. Klajnert-Maculewicz, *Polymers*, 2018, **10**, 187.

8 S. Chandra, S. Dietrich, H. Lang and D. Bahadur, *J. Mater. Chem.*, 2011, **21**, 5729–5737.

9 A. Janaszewska, K. Gradzinska, M. Marcinkowska, B. Klajnert-Maculewicz and W. A. Stanczyk, *Materials*, 2015, **8**, 6062–6070.

10 R. Y. Kannan, H. J. Salacinski, P. E. Butler and A. M. Seifalian, *Acc. Chem. Res.*, 2005, **38**, 879–884.

11 K. Gradzinska, K. Labbecka, A. Kowalewska and W. A. Stanczyk, *Polimery*, 2016, **61**(4), 232–238.

12 W. Zhang and A. H. E. Müller, *Prog. Polym. Sci.*, 2013, **38**, 1121.

13 Z. Zhou and Z. R. Lu, *Future Medicine*, 2014, **9**, 2387.

14 S. Fabritz, S. Hörner, O. Avrutina and H. Kolmar, *Org. Biomol. Chem.*, 2013, **11**, 2224.

15 K. Piorecka, J. Kurjata, M. Stanczyk and W. A. Stanczyk, *Biomater. Sci.*, 2018, **6**(10), 2552–2565.

16 K. Piorecka, E. Radzikowska, J. Kurjata, K. Rozga-Wijas, W. A. Stanczyk and E. Wielgus, *New J. Chem.*, 2016, **40**, 5997–6000.

17 E. Sobierajska, M. Konopka, A. Janaszewska, K. Piorecka, A. Blauz, B. Klajnert-Maculewicz, M. Stanczyk and W. A. Stanczyk, *Materials*, 2017, **10**, 559.

18 S. Ohta, K. Yamura, S. Inasawa and Y. Yamaguchi, *Chem. Commun.*, 2015, **51**, 6422–6425.

19 M. C. Gravel, C. Zhang, M. Dinderman and R. M. Laine, *Appl. Organomet. Chem.*, 1999, **13**, 329–336.

20 Gaussian 16, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B.ennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery Jr, J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman and D. J. Fox, Gaussian, Inc., Wallingford CT, 2016.

21 A. D. Becke, *J. Chem. Phys.*, 1993, **98**, 5648–5652.

22 S. Grimme, J. Antony, S. Ehrlich and H. Krieg, *J. Chem. Phys.*, 2010, **132**, 154104–154119.

23 M. Cossi, N. Rega, G. Scalmani and V. Barone, *J. Comput. Chem.*, 2003, **24**, 669–681.

24 J. J. P. Stewart, *J. Mol. Mod.*, 2013, **19**, 1–32.

25 U. Kanwal, N. I. Bukhari, N. F. Rana, M. Rehman, K. Hussain, N. Abbas, A. Mehmood and A. Raza, *Int. J. Nanomed.*, 2019, **14**, 1–15.

26 Z. Fülop, R. Gref and T. Loftsson, *Int. J. Pharm.*, 2013, **454**, 559–561.

27 P. Agrawal, S. K. Barthwal and R. Barthwal, *Eur. J. Med. Chem.*, 2009, **44**, 1437–1451.

28 R. Anand, S. Ottani, F. Manoli, I. Manet and S. Monti, *RSC Adv.*, 2012, **2**, 2346–2357.

29 N. Martinho, H. Florindo, L. Silva, S. Brocchini, M. Zloh and T. Barata, *Molecules*, 2014, **19**, 20424–20467.

30 S. Hörner, S. Knauer, C. Uth, M. Jöst, V. Schmidts, H. Frauendorf, C. Thiele, O. Avrutina and H. Kolmar, *Angew. Chem., Int. Ed. Engl.*, 2016, **55**, 14842–14846.

